Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study) - Report - MDSpire

Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study)

  • By

  • Nabil E. Omar

  • Shereen Elazzazy

  • Anas Hamad

  • Mohamed Omar Saad

  • Aya Alasmar

  • Sahar M. Nasser

  • Maria Benkhadra

  • Hebatalla M. Afifi

  • Farah I. Jibril

  • Rawan A. Dawoud

  • Mohamed S. Hamid

  • Afnan Alnajjar

  • Arwa O. Sahal

  • Amaal Gulied

  • Hazem Elewa

  • June 19, 2026

  • 0 min

Share

Clinical Report: Erratum on Safety Profile of Immune Checkpoint Inhibitors

Background

Immune checkpoint inhibitors (ICIs) have become standard therapy for various cancers, but their associated toxicities can affect nearly every organ system. This erratum emphasizes the need for accurate reporting in clinical research to ensure transparency and reliability.

Data Highlights

No numerical or trial data is presented in the erratum.

Key Findings

  • The publication of the SAFE-ICI-Q study was funded by the Qatar National Library.
  • Immune-related adverse events (irAEs) can impact multiple organ systems.
  • Prior research has inadequately assessed the clinical characteristics of irAEs over extended timeframes.
  • Accurate funding disclosures are essential for the integrity of clinical research publications.

Clinical Implications

Accurate reporting and acknowledgment of funding sources are critical for maintaining the credibility of clinical studies.

Conclusion

This erratum serves as a reminder of the importance of transparency in clinical research, particularly regarding funding disclosures and the safety of cancer therapies.

Related Resources & Content

  1. Omar NE et al., Frontiers in Immunology, 2025 -- Erratum: Evaluation of the Safety Profile of Immune Checkpoint Inhibitors in Cancer Therapy
  2. Frontiers in Immunology — Comprehensive safety analysis of the clinical spectrum of adverse events associated with immune checkpoint inhibitors based on FAERS
  3. The ASCO Post — Incidence of Major Adverse Cardiac Events in Patients Receiving Immune Checkpoint Inhibitors
  4. Journal of Gastroenterology — Assessment of Pancreatic Damage in Patients Undergoing Treatment with Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis
  5. The ASCO Post — Both Patients and Clinicians Face Challenges in Recognizing and Reporting Immune-Related Adverse Events Related Articles
  6. CE NCCN GUIDELINES® INSIGHTS Management of Immunot
  7. Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review | British Journal of Cancer
  8. Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy | Oncology | JAMA Network Open | JAMA Network

Original Source(s)

Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study)

  • by Nabil E. Omar, Shereen Elazzazy, Anas Hamad, Mohamed Omar Saad, Aya Alasmar, Sahar M. Nasser, Maria Benkhadra, Hebatalla M. Afifi, Farah I. Jibril, Rawan A. Dawoud, Mohamed S. Hamid, Afnan Alnajjar, Arwa O. Sahal, Amaal Gulied, Hazem Elewa

  • June 19, 2026

Related Content

Homologous recombination pathway alterations in basal-like breast cancer

Editorial: The role of immune and stromal mediators in the formation of pre-metastatic and metastatic niches: the gateway to metastasis

Epilepsy characteristics and outcomes in patients with pleomorphic xanthoastrocytomas